These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12817773)

  • 1. Surrogates for fracture endpoints in clinical trials.
    Khosla S
    J Bone Miner Res; 2003 Jun; 18(6):1146-9. PubMed ID: 12817773
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications critically evaluated: hormone-domain hot flashes].
    MMW Fortschr Med; 2003 Nov; 145(46):5-8. PubMed ID: 14699822
    [No Abstract]   [Full Text] [Related]  

  • 5. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Increase in bone mineral density and its effect on fracture risk].
    Sone T
    Clin Calcium; 2005 Apr; 15(4):625-9. PubMed ID: 15802775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of osteoporotic fractures].
    Kannus P
    Duodecim; 1999; 115(7):759-64. PubMed ID: 11859509
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone fractures after menopause.
    ESHRE Capri Workshop Group
    Hum Reprod Update; 2010; 16(6):761-73. PubMed ID: 20427370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ethics of placebo in studies with fracture end points in osteoporosis.
    Stein CM; Ray WA
    N Engl J Med; 2010 Sep; 363(14):1367-70; discussion e21. PubMed ID: 20879888
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
    Lufkin EG; Sarkar S; Kulkarni PM; Ciaccia AV; Siddhanti S; Stock J; Plouffe L
    Curr Med Res Opin; 2004 Mar; 20(3):351-7. PubMed ID: 15025844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
    Cortet B
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fewer fractures after just 6 months. Fast help for tired bones].
    MMW Fortschr Med; 2002 Nov; 144(48):61. PubMed ID: 12532551
    [No Abstract]   [Full Text] [Related]  

  • 15. Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials.
    Liberman UA; Hochberg MC; Geusens P; Shah A; Lin J; Chattopadhyay A; Ross PD
    Int J Clin Pract; 2006 Nov; 60(11):1394-400. PubMed ID: 17026515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of osteoporosis and fractures.
    Ullom-Minnich P
    Am Fam Physician; 1999 Jul; 60(1):194-202. PubMed ID: 10414638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of osteopenic women at high risk of fracture: the OFELY study.
    Sornay-Rendu E; Munoz F; Garnero P; Duboeuf F; Delmas PD
    J Bone Miner Res; 2005 Oct; 20(10):1813-9. PubMed ID: 16160738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
    Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
    J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.